Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Sells $57,000.00 in Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Sharon Townson sold 3,000 shares of the business’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $19.00, for a total transaction of $57,000.00. Following the completion of the transaction, the insider directly owned 67,845 shares of the company’s stock, valued at approximately $1,289,055. This represents a 4.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Monte Rosa Therapeutics Stock Performance

Shares of GLUE opened at $18.31 on Friday. The business’s fifty day moving average price is $18.65 and its two-hundred day moving average price is $18.48. The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of -12.37 and a beta of 1.60. Monte Rosa Therapeutics, Inc. has a 52 week low of $4.12 and a 52 week high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.06). The firm had revenue of $4.21 million for the quarter, compared to analyst estimates of $10.95 million. Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. As a group, research analysts forecast that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Wall Street Zen cut shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Wells Fargo & Company cut their price target on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 18th. JPMorgan Chase & Co. raised their price target on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Guggenheim dropped their price objective on Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a report on Wednesday, March 18th. Finally, Weiss Ratings upgraded Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, May 11th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Monte Rosa Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $32.50.

Institutional Investors Weigh In On Monte Rosa Therapeutics

Several hedge funds have recently bought and sold shares of GLUE. AQR Capital Management LLC acquired a new position in shares of Monte Rosa Therapeutics in the 1st quarter valued at $1,065,000. Goldman Sachs Group Inc. increased its position in shares of Monte Rosa Therapeutics by 122.7% during the first quarter. Goldman Sachs Group Inc. now owns 356,112 shares of the company’s stock worth $1,652,000 after acquiring an additional 196,238 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Monte Rosa Therapeutics during the first quarter worth $76,000. Geode Capital Management LLC raised its holdings in shares of Monte Rosa Therapeutics by 12.0% during the second quarter. Geode Capital Management LLC now owns 1,124,160 shares of the company’s stock worth $5,071,000 after acquiring an additional 120,098 shares during the period. Finally, American Century Companies Inc. lifted its position in Monte Rosa Therapeutics by 301.4% in the 2nd quarter. American Century Companies Inc. now owns 403,045 shares of the company’s stock valued at $1,818,000 after acquiring an additional 302,639 shares in the last quarter. 79.96% of the stock is currently owned by institutional investors and hedge funds.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.